SBRI Healthcare awards £2.5 million to accelerate innovations that narrow health inequalities in maternity care
Posted:
SBRI Healthcare, an Accelerated Access Collaborative initiative, in partnership with the Health Innovation Network, has awarded £2.5m for the progression of five innovations that help narrow inequalities in maternity care.
Kisqali, a key targeted therapy for breast cancer from Novartis, until now has been indicated only for patients with metastatic disease. But, the Food and Drug Administration approved Kisqali in combination with hormone therapy for patients with certain early-stage breast cancers. …
Wearable technology that monitors our bodies can be helpful and harmful.
Wearable technology affords the opportunity to check, re-check, and check again, leading to fixation.
Read the full article in the Psychology Today blog post here.